Bioline Rx Ltd BLRX

NAS: BLRX | ISIN: US09071M2052   26/04/2024
0,612 USD (+6,31%)
(+6,31%)   26/04/2024
Grafiek Bioline Rx Ltd Grafiek Bioline Rx Ltd

Bioline Rx Ltd in het nieuws

17 april 2024 · BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting · Persbericht

10 april 2024 · BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement · Persbericht

1 april 2024 · BioLineRx Announces $6 Million Registered Direct Offering · Persbericht

26 maart 2024 · BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates · Persbericht

20 maart 2024 · BioLineRx to Report 2023 Annual Financial Results on March 26, 2024 · Persbericht

4 maart 2024 · BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production · Persbericht

28 februari 2024 · BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) · Persbericht

16 februari 2024 · BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR® · Persbericht

21 december 2023 · BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease · Persbericht

13 november 2023 · BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 · Persbericht

Profiel Bioline Rx Ltd

Fabricage van farmaceutische preparaten
Farmaceutische producten: Andere
Gezondheidstechnologie
Productie

CEO: Philip Serlin

Werknemers: 58

Aandelen Bioline Rx Ltd

Beurswaarde: 48,89 miljoen USD

Effecten: 79,94 miljoen

Beta: 1,44

Mijn selecties